

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 9

**Complete if Known**

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
|                        |                          | Number - Kind Code <sup>2</sup> (If known) |                                |  |   |
|                        |                          | 4,943,533                                  | 07-24-1990                     | John Mendelsohn                                    |   |
|                        |                          | 5,457,105                                  | 10-10-1995                     | Andrew J. Barker                                   |   |
|                        |                          | 5,558,864                                  | 09-24-1996                     | Mary M. Bendig                                     |   |
|                        |                          | 5,770,599                                  | 06-23-1998                     | Keith H. Gibson                                    |   |
|                        |                          | 5,747,498                                  | 05-05-1998                     | Rodney C. Schnur                                   |   |
|                        |                          | 5,891,996                                  | 04-06-1999                     | Cristina M. Mateo<br>De Acosta Del Rio             |   |
|                        |                          | 6,200,598                                  | 03-13-2001                     | David Needham                                      |   |
|                        |                          | 6,235,883                                  | 05-22-2001                     | Aya Jakobovits                                     |   |
|                        |                          | RE 39496                                   | 02-27-2007                     | Paul J. Scheuer                                    |   |
|                        |                          | 6,344,455                                  | 02-05-2002                     | Alexander James<br>Bridges                         |   |
|                        |                          | 6,391,874                                  | 05-21-2002                     | George Stuart<br>Cockerill                         |   |
|                        |                          | 6,713,485                                  | 03-30-2004                     | Malcolm Clive<br>Carter                            |   |
|                        |                          | 6,727,256                                  | 04-27-2004                     | Malcolm Clive<br>Carter                            |   |
|                        |                          | 6,900,221                                  | 05-31-2005                     | Timothy Norris                                     |   |
|                        |                          | 7,323,444                                  | 01-29-2008                     | Miguel Angel<br>Izquierdo Delso                    |   |
|                        |                          | 7,482,429                                  | 01-27-2009                     | Fernando Albericio                                 |   |
|                        |                          | 7,507,708                                  | 03-24-2009                     | Glynn Thomas<br>Faircloth                          |   |
|                        |                          | 7,683,028                                  | 03-23-2010                     | Glynn Thomas<br>Faircloth                          |   |
|                        |                          | 2004/0071768                               | 04-15-2004                     | Andreas H. Sarris                                  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document  | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>3</sup> |
|-----------------------|--------------------------|--|--------------------------------|---|--|----------------|
|                       |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup><br>(If known) |                                |   |  |                |
|                       |                          |  |                                |   |  |                |
|                       |                          |  |                                |   |  |                |
|                       |                          |  |                                |   |  |                |
|                       |                          |  |                                |   |  |                |

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw the through citation if not in conformance and not considered. Include copy of this form with each communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. <sup>6</sup> If possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **2** of **9**

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     |                       | Aillon, K. L. et al., "Effects of Nanomaterial physicochemical properties on in vivo toxicity," Adv. Drug. Deliv. Rev. 2009, 61, 457-466  |                |
|                     |                       | Alivisatos, P., "The use of nanocrystals in biological detection," Nature Biotech. 2004, 22, 47-52  |                |
|                     |                       | Arora, A et al., "Role of Tyrosine Kinase Inhibitors in Cancer Therapy," Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 971-979  |                |
|                     |                       | Baba, T. et al., Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations [abstract] In: Proceedings of the 39 <sup>th</sup> Annual Meeting on Women's Cancer of the Society of Gynecologic Oncologists; 2008 March 9-12; Tampa, Florida. Chicago (IL); SGO; 2008. Abstract no 160; and the corresponding poster presented in said congress |                |
|                     |                       | Bensebaa, F. et al., "XPS study of metal-sulfur bonds in metal-alkanethiolate materials," Surf. Sci. 1998, 405, L472-L476   |                |
|                     |                       | Boisselier, E. et al., "Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity," Chem. Soc. Rev. 2009, 38, 1759-1782  |                |
|                     |                       | Bruce, J. Y. et al., Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations [abstract] IN: Proceedings of the 44 <sup>th</sup> Annual Meeting of the American Society of Clinical Oncology; 2008 May 30 – Jun 3; Chicago, IL. Alexandria (VA); ASCO; 2008. Abstract no 2513; and the corresponding poster presented in said congress  |                |
|                     |                       | Chen et al., "Methotrexate Conjugated to Gold Nanoparticles Inhibits Tumor Growth in a Syngeneic Lung Tumor Model," Mol. Pharmaceutics, 2007, 4, 713-722  |                |
|                     |                       | Chithrani et al., "Elucidating the Mechanism of Cellular Uptake and Removal of Protein-Coated Gold Nanoparticles of Different Sizes and Shapes," Nano Lett. 2007, 7, 1542-1550  |                |

|                    |                 |  |
|--------------------|-----------------|--|
| Examiner Signature | Date Considered |  |
|--------------------|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. <sup>5</sup> If it is possible. <sup>6</sup> Applicant is to also check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and completing the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 9

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

### NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials * | Cite<br>No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
|------------------------|--------------|--|----------------|
|                        |              | Coronado, C. et al., "Elisidepsin," <i>Drugs of the Future</i> , 2010, 35, 287-296   |                |
|                        |              | Evans, T. R. et al., Phase I dose-escalating, study of PM02734 in a 24-hour infusion schedule every 21 days in advance solid tumors [abstract] In: <i>Proceedings of the 45<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology</i> ; 2009 May 29 – Jun 2; Orlando, FL. Alexandria (VA): ASCO; 2009. Abstract nr 2511; and the corresponding poster presented in said congress            |                |
|                        |              | Faircloth, G. T. et al., Selective Antitumor Activity of Kahalalide F, A Marine-Derived Cyclic Dipeptide [abstract]. In: <i>Proceedings of the 94<sup>th</sup> Annual Meeting of the American Association for Cancer Research</i> ; Vol. 42, March 2001. Abstract no 1140  |                |
|                        |              | Frens, G. et al., "Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions," <i>Nature Phys. Sci.</i> , 1973, 241, 20-22  |                |
|                        |              | Galmarini, C. M., New marine anticancer agents in development [abstract] In: <i>6<sup>th</sup> European Spring Oncology Conference</i> ; 2010 Jun 22-25; Marbella, Málaga. España: ESOC; 2010. Vol. 12, p 26; and the corresponding presentation presented in said congress  |                |
|                        |              | García-Rocha, M. et al., "The antitumoral compound Kahalalide F acts on cell lysosomes," <i>Cancer Lett.</i> , 1996, 99, 43-50   |                |
|                        |              | Georger, B. et al., Evaluation of the marine compound PM02734 against a pediatric tumor cell line panel by ITCC preclinical drug evaluation program [abstract] In: <i>20<sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics</i> ; 2008 Oct 22-24; Geneva, Switzerland. Philadelphia (PA): AACR; 2008. Abstract no 181; and the corresponding poster presented in said congress |                |
|                        |              | Gibson et al., "Paclitaxel-Functionalized Gold Nanoparticles," <i>J. Am. Chem. Soc.</i> , 2007, 129, 11653-11661   |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document on the basis of the code (USPTO Standard ST 3). \*For duplicate patent documents, the indication of the year of the origin of the foreign must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FILES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 9

## Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
|---------------------|-----------------------|--|----------------|
|                     |                       | Giljohann, D. A. et al., "Gold Nanoparticles for biology and medicine," <i>Angew. Chem. Int. Ed.</i> , 2010, 49, 3280-3294   |                |
|                     |                       | Hernandez-Losa, J. et al., Downregulation of ErbB3 expression and inhibition of Akt pathway by PM02734; <i>in vitro</i> synergism of the combination with cisplatin in breast, colon and lung cancer cell lines [abstract] In: Proceedings of the 99 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract no 1473; and the corresponding poster presented in said congress |                |
|                     |                       | Herrero, A. B. et al., "Levels of SCS7/FA2H-Mediated Fatty Acid 2-Hydroxylation Determine the Sensitivity of Cell to Antitumor PM02734," <i>Cancer Res.</i> , 2008, 68, 9779-9787  |                |
|                     |                       | Hosta, L. et al., "Conjugation of Kahalalide F with Gold Nanoparticles to Enhance In Vitro Antitumoral Activity," <i>Bioconj. Chem.</i> , 2008, 20, 138-146  |                |
|                     |                       | Hynes, N. E. et al., "ErbB Receptors and Cancer: The Complexity of Targeted Inhibitors," <i>Nature Rev.</i> , 2005, 5, 341-354   |                |
|                     |                       | Jain et al., "Calculated Absorption and Scattering Properties of Gold Nanoparticles of Different Size, Shape and Composition: Applications in Biological Imaging and Biomedicine," <i>J. Phys. Chem. B</i> 2006, 110, 7238-7248  |                |
|                     |                       | Jannat, M. L. et al., Kahalalide F (KF) induces cell death in Her2/neu overexpressing breast cancer cells that is independent of caspade, cathepsin B, and cathepsin D activity [abstract]. In: Proceedings of the 2 <sup>nd</sup> International Symposium on Signal Transduction Modulators in Cancer Therapy; 2003 October 23-25; Amsterdam, 2003:60. Abstract no B02  |                |

Examiner Signature

Date Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with most communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 501.04. <sup>3</sup> Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>6</sup> If possible. <sup>7</sup> Applicant is to place a check mark here if English language. Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 9

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
|---------------------|-----------------------|--|----------------|
|                     |                       | Janmaat, M. L. et al., "Khalafide F induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling," Mol. Pharm., 2005, 68, 502-510   |                |
|                     |                       | Kim et al., "Designed Fabrication of Multifunctional Magnetic Gold Nanoshells and Their Application to Magnetic Resonance Imaging Photothermal Therapy," Angew. Chem. Int. Ed., 2006, 45, 7754-7758  |                |
|                     |                       | Kogan, M. J. et al., "Nanoparticle-Mediated Local and Remote Manipulation of Protein Aggregation," Nano Lett., 2006, 6, 110-115  |                |
|                     |                       | Ling, Y.-H. et al., "Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27 <sup>KIP1</sup> Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines," Molecular Pharmacology, 2007, 72(2), 248-258  |                |
|                     |                       | Ling, Y.-H. et al., "In Vitro Cytotoxicity, Cellular Pharmacology, and DNA Lesions Induced by Annamycin, an Anthracycline Derivative with High Affinity for Lipid Membranes," Cancer Res., 1993, 53, 1583-1589   |                |
|                     |                       | Ling, Y.-H. et al., Iravalec (PM02734) induces caspase-independent autophagic cell death in human non-small cell lung cancer cell lines through the inhibition of akt/mTOR signaling pathways and activation of death associated protein kinase [abstract] In: Proceedings of the 100 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2656; and the corresponding poster presented in said congress |                |
|                     |                       | Ling, Y.-H. et al., "Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models," Eur. J. Cancer, 2009, 45, 1855-1864   |                |
|                     |                       | Mayer, A. M. S. et al., "The Odyssey of marine pharmaceuticals: a current pipeline perspective," Cell, 2010, 31, 255-265   |                |

|                    |                 |  |
|--------------------|-----------------|--|
| Examiner Signature | Date Considered |  |
|--------------------|-----------------|--|

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformity with MPEP 809. Draw line through citation if not in conformity and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Prior Office that issued the document or, by the then later code, (WFO) Standard (ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Find of document by the appropriate symbols as indicated on the document under NISO Standard ST-31, if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is in the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 9

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|                                 |                       | Medina, L. et al., Investigation of the Effects of Kahalalide F (PM92102) Against Human Tumor Specimens taken directly from patients [abstract]. In: Proceedings of the 94 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; Vol. 42, March 2001, Abstract no 1139  |                |
|                                 |                       | Molina-Guijarro, J. M. et al., Modulation of the early cytotoxic effects of Irvalc® by zinc and DIDS in lung tumor cells [abstract] In: Proceedings of the 101th Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract no 4454; and the corresponding poster presented in said congress   |                |
|                                 |                       | Molina-Guijarro, et al., PM02734, a new marine-derived antitumoral compound, has rapid effects on membrane integrity and permeability in tumor cells [abstract] In: Proceedings of the 100 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia PA: AACR, 2009. Abstract no 888; and the corresponding poster presented in said congress                          |                |
|                                 |                       | Osaki, et al., "A Quantum Dot Conjugated Sugar Ball and Its Cellular Uptake. On the size Effects of Endocytosis in the Subviral Region" J. Am. Chem. Soc., 2004, 126, 6520-6521   |                |
|                                 |                       | Paciotti, G. F. et al., "Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery," Drug Delivery 2004, 11, 169-183   |                |
|                                 |                       | Paciotti, G. F. et al., "Colloidal Gold Nanoparticles: A Novel Nanoparticle Platform for Developing Multifunctional Tumor-Targeted Drug Delivery Vectors" Drug Dev.Re., 2006, 67, 47-54   |                |
|                                 |                       | Pérez-Soler, R. et al., PM02734 (Irvalc), a novel synthetic cyclic peptide compound, induces caspase-independent autophagic cell death in human non-small cell lung cancer cell lines through the inhibition of Akt/mTOR signaling pathways and activation of DARK. [abstract] In: AACR-NCL-EORTC Symposium on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA. Philadelphia (PA): AACR; 2009. Abstract no C2 |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the request must precede the serial number of the patent document. \*Not of document by the appropriate symbols as indicated on the document under WIPO Standard ST 38 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 37 CFR 1.14. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 9

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     |                       | Pérez-Soler, R. et al., Synergism between PM02734 and erlotinib in human non-small cell lung cancer cell lines [abstract] In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26; San Francisco, CA. Philadelphia (PA): AACR; 2007. Abstract no C179; and the corresponding poster presented in said congress   |                |
|                     |                       | Provencio, M. et al. "Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?" Clin. Lung Cancer, 2009, 10, 295-300  |                |
|                     |                       | Sagara, T. et al., "Electroreflectance Study of Gold nanoparticles Immobilized on an Aminoalkanethiol Monolayer Coated on a Polycrystalline Gold Electrode Surface" J. Phys. Chem. B 2002, 106, 1205-1212   |                |
|                     |                       | Santabarbara, P. Present and Future of Marine Anticancer Compounds [abstract] In: 5 <sup>th</sup> European Spring Oncology Conference; 2008 Jun 25-27; Marbella, Málaga. España: ESOC; 2008. Abstract no 20   |                |
|                     |                       | Sasak, H. et al., PM02734 Cytotoxicity In Vitro and Pharmacokinetics [Poster] In: Proceedings of the 97 <sup>th</sup> Annual Meeting of the American association for Cancer Research; 2006 April 1-5; Whashington, DC. Philadelphia (PA): AACR; 2006. Abstract no 1911  |                |
|                     |                       | Serova, M. et al., Antiproliferative Effects of PM02734, a novel cyclic peptide compared with currently used Erb-B Inhibitors, in a panel of human cancer cells lines characterized for Erb-B express. In: 20 <sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 2008 Oct 22-24; Geneva, Switzerland. Philadelphia (PA): AACR; 2008. Abstract no 317; and the corresponding poster presented in said congress |                |
|                     |                       | Serova, M. et al., Characterization of genetic factors associated with sensitivity to Ivalcic, a novel marine-derived compound. In: Proceedings of the 100 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract no 857; and the corresponding poster presented in said congress  |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with most communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See: Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Error Office that issued the document by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 10. If possible, Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. This information is required to obtain, or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 9

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|---------------------|-----------------------|---|----------------|
|                     |                       | Serova, M. et al., Epithelial-to-mesenchymal transition (EMT) in resistance to the antiproliferative effects of elisidepsin (Irvalec <sup>TM</sup> ), a novel marine-derived depsipeptide, in colon cancer cells [abstract] In: AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA, Philadelphia (PA): AACR; 2009. Abstract no B151; and the corresponding poster presented in said congress |                |
|                     |                       | Serova, M. et al., Irvalec, a novel marine cyclic peptide, enhances the antiproliferative effects of other anticancer drugs in human cancer cell lines [abstract] In: Proceedings of the 100 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO, Philadelphia (PA): AACR; 2009. Abstract no 4569; and the corresponding poster presented in said congress                             |                |
|                     |                       | Serova, M. et al., Molecular mechanism associated with sensitivity/resistance to PM02734 (Irvalec®), a novel marine-derived cyclic depsipeptide [abstract] In: Proceedings of the 101 <sup>th</sup> Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC, Philadelphia (PA): AACR, 2010. Abstract no 1542; and the corresponding poster presented in said congress                                |                |
|                     |                       | Sewell et al., "The Mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines" European J. Cancer, 2005, 41, 1637-1644   |                |
|                     |                       | Shilabin et al., "Lysosome and Her3 (ErbB3) Selective Anticancer Agent Kahalalide F: Semisynthetic Modifications and Antifungal Nead-Exploration Studies" J. Med. Chem. 2007, 50, 4340-4350   |                |
|                     |                       | Steeh, N. et al. "Small Molecule Tyrosine Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments" Annals of Surgical Oncology 2006, 14, 942-953  |                |
|                     |                       | Suárez, Y. et al., "Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells" Mol. Cancer Ther. 2003, 2, 863-872  |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with most communicative to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Remarks/Comments of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document by the two letter code (WIPO Standard ST 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the grant of the Japanese must precede the serial number of the patent document. <sup>5</sup>Final of document by the appropriate symbols as indicated on the document under WIPO Standard ST. If it is possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 9

### Complete if Known

|                        |                             |
|------------------------|-----------------------------|
| Application Number     | 10/570,734                  |
| Filing Date            | October 18, 2006            |
| First Named Inventor   | Fernando Albericio Palomera |
| Art Unit               | 1654                        |
| Examiner Name          | Ronald T. Niebauer          |
| Attorney Docket Number | 13566.105010                |

### NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials * | Cite<br>No. † | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>2</sup> |
|------------------------|---------------|--|----------------|
|                        |               | Sun, L. et al., "Functional Gold Nanoparticle-Peptide Complexes as Cell-Targeting Agents" <i>Langmuir</i> 2008, 24, 10293-10297  |                |
|                        |               | Tkachenko et al., "Multifunctional Gold Nanoparticles-Peptide Complexes for Nuclear Targeting," <i>J. Am. Chem. Soc.</i> 2003, 125, 4700-4701  |                |
|                        |               | Tkachenko et al., "Cellular Trajectories of Peptide-Modified Gold Nanoparticles: Comparison of Nuclear Localization Signals and Peptide Transduction Domains," <i>Bioconjugate Chem.</i> 2004, 15, 482-490   |                |
|                        |               | Varadi, T. et al., C-erbB3 protein modifications are secondary to severe cell membrane alterations induced by Iravalec treatment in CHO cells [abstract] In: Proceedings of the 101th Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-20; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 4464; and the corresponding poster presented in said congress |                |
|                        |               | Visaria, R. K. et al., "Enhancement of tumor thermal therapy using gold nanoparticle assisted tumor necrosis factor- $\alpha$ delivery" <i>Mol. Cancer Ther.</i> 2006, 5, 1014-1020  |                |
|                        |               | Wosikowski et al., "Identification of Epidermal Growth Factor Receptor and c-erbB2 Pathway Inhibitors by Correlation With Gene Expression Patterns" <i>J. Natl. Cancer Inst.</i> 1997, 89, 1505-1515   |                |
|                        |               | Xu et al., "Inorganic nanoparticles as carriers for efficient cellular delivery," <i>Chem. Eng. Sci.</i> 2006, 61, 1027-1040   |                |
|                        |               | Yin, J. et al., "Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma" <i>Rapid Commun. Mass. Spectrom.</i> 2006, 20, 2735-2740  |                |
|                        |               | Zou, Y. et al. Antitumor activity of Iravalec (PM02734) against lung cancer xenografts [abstract] In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract no 5466; and the corresponding poster presented in said congress  |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind's Control of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document by the two-letter code (WIPO Standard ST 3). For separate patent documents, the indication of the point of the stage of the document must precede the serial number of the patent document. †Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. If it is possible. Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 37 CFR 1.14. This information is required to obtain or retain a benefit by the public which is in file (by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.